NCT06221475 - A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

April 5, 2024

Study Completion Date

May 8, 2024

Conditions

Advanced Non-small Cell Lung CancerEGFR MutationHER2 MutationHealthy Volunteers

Interventions

DRUG

BAY2927088 coated tablet 10 mg

4 coated tablets (10 mg) per single dose 30 min after a light meal

DRUG

[14C]-BAY2927088 solution for infusion

IV infusion 15 min ending at 2 hours oral post-dose

DRUG

[14C]-BAY2927088 oral solution

After a light meal

Trial Locations (1)

ICON plc, Groningen